Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab in Locally Advanced Pancreatic Cancer (LAPIS)
NCT03941093Phase 3Completed
- Sponsor
- FibroGen
- Start
- May 2019
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in pancreatic ductal adenocarcinoma (PDAC) comparing Pamrevlumab + Chemo with Placebo + Chemo (2 arms). Primary endpoint: Overall Survival up to 5 years. Started May 2019; status: completed.
02
Drugs
pamrevlumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03941093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941093.